Paysign : Patient Affordability Drives 51% Revenue Growth and Significant …

Published: 2026-05-12 16:12:22 ET PAYS

Published on 05/12/2026 at 04:12 pm EDT

Mix Shift Continues to Deliver Expansion in Gross and Operating Margin

Strong Balance Sheet Enables Continued Investment for Profitable Growth

HENDERSON, Nev. - May 12, 2026 - (Business Wire) - Paysign, Inc. (NASDAQ: PAYS), a leading provider of patient affordability programs, donor compensation solutions, engagement and management platforms and integrated payment processing for the life sciences industries, today announced financial results for the first quarter 2026.

"Paysign delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction and the scalability of the platform we've built," said Mark Newcomer, President and CEO of Paysign. "Our plasma donor compensation business continues to perform exceptionally well, and the reception to our SaaS solutions from collectors and plasmapheresis manufacturers across the U.S., Europe and Asia reinforces our conviction that purpose-built technology, backed by deep industry expertise, creates a competitive advantage. Patient affordability emerged as our largest revenue contributor in the quarter, with 135 active programs and a strong pipeline that reflects the trust pharmaceutical manufacturers place in Paysign to help patients access and afford the therapies they need. As this business grows, we are positioned to deliver long-term value for our shareholders, our customers and the patients we serve."

Click here for the full earnings release.

Disclaimer

Paysign Inc. published this content on May 12, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 12, 2026 at 20:11 UTC.